logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Cost-utility analysis of recombinant human erythropoietin in cancer patients with anemia induced by chemotherapy in Thailand (in Thai language)

Home > Research Projects > Strategy 3 : HTA Research > Cost-utility analysis of recombinant human erythropoietin in cancer patients with anemia induced by chemotherapy in Thailand (in Thai language)

Project Code

01-314-2550

Research team

Researchers

Jirapan Roungrong, PhD. (Candidate)

Co - Researcher

Usa Chaikledkaew, PhD.

Yot Teerawattananon, PhD.

Project Details

Strategies
Category
Support
Tags
Project duration

Start: - 2007
End: -

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 1748

Publish date29 November 2011 14:46

Project Summary

An increase in the number of cancer patients with anemia has been observed in Thailand due to an increase of cancer patients and the use of chemotherapy for treatment of cancers that cause bone marrow suppression. Although blood transfusion is an effective way of increasing the hemoglobin level in anemic patients, several limitations do exist with this approach. These limitations include: a severe shortage of blood donations and the high cost of screening of blood donations. As a result, an innovative recombinant human erythropoietin (rHuEPO ) has been considered as an alternative choice for the treatment of anemia caused by chemotherapy. However, a cost-utility analysis on rHuEPO for treating anemic cancer patients induced by chemotherapy compared to blood transfusion alone found that it is not cost-effective under the Thai health care setting.

Documents

Activity

โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ ชั้น 6 อาคาร 6 กรมอนามัย กระทรวงสาธารณสุข ถ.ติวานนท์ อ.เมือง จ.นนทบุรี 11000

โทร : +662-590-4549 , +662-590-4374-5
โทรสาร : +662-590-4369
E-mail : [email protected]

© Copyright - HITAP 2014
Top